SYK vs TMCI
SYK: A diversified medical technology leader offering surgical equipment, orthopedic robotics, and minimally invasive neurovascular products that collectively serve over 150 million patients annually across 61 countries. TMCI: Treace is a focused orthopedic medical device company specializing in innovative 3D bunion correction and foot surgery systems for hospitals and surgical centers.
Side-by-side fundamentals
| Metric | SYK | TMCI | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $309.24 | $3.97 | |
| Market cap as of 2026-07-23 | $119.6B | $258M | |
| P/E as of 2026-07-23 | 35.83 | n/a | |
| PEG as of 2026-07-23 | 3.29 | -0.35 | TMCI lower |
| Net margin as of 2026-07-23 | +13.2% | -29.4% | SYK higher |
| Gross margin as of 2026-07-23 | +64.2% | +79.7% | TMCI higher |
| Operating margin as of 2026-07-23 | +19.7% | -28.2% | SYK higher |
| ROE as of 2026-07-23 | +15.1% | -69.5% | SYK higher |
| ROA as of 2026-07-23 | +7.1% | -31.4% | SYK higher |
| Debt / equity as of 2026-07-23 | 0.64 | 0.72 | SYK lower |
| Revenue growth (YoY) as of 2026-07-23 | +8.8% | -1.7% | SYK higher |
| Revenue CAGR (3y) SEC XBRL | +10.8% | +14.5% | TMCI higher |
| Dividend yield as of 2026-07-23 | +1.1% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-07-23 | 0.78 | 1.40 | |
| 1-year return as of 2026-07-22 close | -21.7% | -26.0% | SYK higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.